{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.96","upperLimit":"17.87","value":"13.57"},{"groupId":"OG001","lowerLimit":"10.09","upperLimit":"16.66","value":"13.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from date of randomization to date of death due to any cause. Kaplan-Meier methodology was used to estimate the median overall survival for each treatment group","dispersionType":"95% Confidence Interval","groups":[{"description":"The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred at data cutoff of 28Feb2008, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.","id":"OG000","title":"RAD001 +BSC"},{"description":"Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression at data cutoff of 28Feb2008, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"Full analysis set was performed on the intent-to-treat population which consisted of all randomized patients.","reportingStatus":"POSTED","timeFrame":"Assessed every month up to 2 years after the last patient was randomized into the study from the date of randomization to the time of death. (Data cutoff was 15Nov2009)","title":"Overall Survival (OS) Assessed by the Monthly Overall Survival Assessments","type":"SECONDARY","unitOfMeasure":"Months"}